Cure Rates After a Single Dose of Radioactive Iodine to Treat Hyperthyroidism: The Fixed-Dose Regimen
Open Access
- 23 August 2022
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28316
Abstract
Radioactive iodine (RAI) has been used to treat hyperthyroidism for more than 70 years. Cure rates after RAI therapy range between 80% and 100%, with some patients requiring two or more doses. There is continued debate over which dosing regimen is optimal. We evaluated our cure rates after giving a single dose of radioactive iodine to treat hyperthyroidism using the fixed-dose regimen as opposed to the calculated-dose regimen. We retrospectively reviewed the clinical records of patients who had received their first single dose of RAI between 2016 and 2021. The patients had clinical and biochemical assessments every six weeks until six months post-RAI therapy, then every three months thereafter, if still not cured. Patients were deemed cured if they developed persistent hypothyroidism or euthyroidism after a single dose of RAI. The data included baseline demographics, adverse events, and cure rates after RAI treatment. One hundred and thirty-eight patients received their first dose of RAI during the study period. Their mean ± standard deviation (SD) age was 56.9 ± 15.3 years, and there were 101 women and 37 men. The median duration of hyperthyroidism was 34 months, and 62% of the cases were affected by Graves’ disease. A majority of patients (90%) were on an antithyroid drug prior to RAI therapy. The median (interquartile range) dose of RAI received by the group was 559 (546-577) megabecquerels (MBq). Four patients (2.9%) reported adverse events shortly after receiving RAI. Our overall cure rate was 87.7% amongst patients who received a single dose of RAI therapy. This number consisted of 96 patients (69.6%) who developed hypothyroidism and 25 patients (18.1%) who remained euthyroid. Our one-year cure rate was 84.1%. Further analysis revealed that women had a greater cure rate than men over the study period (92% vs 75.7%, p = 0.017). We have evaluated cure rates after a single dose of RAI therapy for the treatment of hyperthyroidism at our center. Our results are comparable to those reported at other centers using a similar dosing regimen.Keywords
This publication has 12 references indexed in Scilit:
- Thyroid disease: assessment and management2019
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of ThyrotoxicosisThyroid®, 2016
- Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous PopulationInternational Journal of Endocrinology, 2016
- Radioiodine Therapy in Benign Thyroid Diseases: Effects, Side Effects, and Factors Affecting Therapeutic OutcomeEndocrine Reviews, 2012
- The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0Journal of Nuclear Medicine, 2012
- A prospective randomized study of the efficacy and cost-effectiveness of high and low dose regimens of I-131 treatment in hyperthyroidism.2011
- Radioiodine I-131 for the therapy of graves' disease.2009
- High Dose131I Therapy for the Treatment of Hyperthyroidism Caused by Graves’ DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2002
- The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham SurveyClinical Endocrinology, 1995
- Ablative radioiodine therapy for hyperthyroidism: long term follow up study.BMJ, 1984